Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Phenotypic vs. target-based drug discovery for first-in-class medicines.

Swinney DC.

Clin Pharmacol Ther. 2013 Apr;93(4):299-301. doi: 10.1038/clpt.2012.236.

PMID:
23511784
2.

The contribution of mechanistic understanding to phenotypic screening for first-in-class medicines.

Swinney DC.

J Biomol Screen. 2013 Dec;18(10):1186-92. doi: 10.1177/1087057113501199. Epub 2013 Aug 27.

PMID:
23983234
3.

Drug discovery for neglected diseases: molecular target-based and phenotypic approaches.

Gilbert IH.

J Med Chem. 2013 Oct 24;56(20):7719-26. doi: 10.1021/jm400362b. Epub 2013 Sep 9. Review.

4.

Neoclassic drug discovery: the case for lead generation using phenotypic and functional approaches.

Lee JA, Berg EL.

J Biomol Screen. 2013 Dec;18(10):1143-55. doi: 10.1177/1087057113506118. Epub 2013 Sep 30. Review.

PMID:
24080259
5.

How were new medicines discovered?

Swinney DC, Anthony J.

Nat Rev Drug Discov. 2011 Jun 24;10(7):507-19. doi: 10.1038/nrd3480. Review.

PMID:
21701501
6.

Clinical relevance of target identity and biology: implications for drug discovery and development.

Patel AC.

J Biomol Screen. 2013 Dec;18(10):1164-85. doi: 10.1177/1087057113505906. Epub 2013 Sep 30. Review.

PMID:
24080260
7.

Target identification of small molecules based on chemical biology approaches.

Futamura Y, Muroi M, Osada H.

Mol Biosyst. 2013 May;9(5):897-914. doi: 10.1039/c2mb25468a. Review.

PMID:
23354001
8.

Applications of chemogenomic library screening in drug discovery.

Jones LH, Bunnage ME.

Nat Rev Drug Discov. 2017 Apr;16(4):285-296. doi: 10.1038/nrd.2016.244. Epub 2017 Jan 20. Review.

PMID:
28104905
9.

Application of chemistry-based functional proteomics to screening for novel drug targets.

Yuan K, Lei Y, Huang C.

Comb Chem High Throughput Screen. 2010 Jun;13(5):414-21. Review.

PMID:
20156143
10.

Chemoproteomic approaches to drug target identification and drug profiling.

Bantscheff M, Drewes G.

Bioorg Med Chem. 2012 Mar 15;20(6):1973-8. doi: 10.1016/j.bmc.2011.11.003. Epub 2011 Nov 9. Review.

PMID:
22130419
11.

Opportunities and challenges in phenotypic drug discovery: an industry perspective.

Moffat JG, Vincent F, Lee JA, Eder J, Prunotto M.

Nat Rev Drug Discov. 2017 Aug;16(8):531-543. doi: 10.1038/nrd.2017.111. Epub 2017 Jul 7. Review.

PMID:
28685762
12.

Pathways and targets--opposite approaches to success?

Blundy K.

Drug Discov Today. 2012 Mar;17(5-6):183-4. doi: 10.1016/j.drudis.2011.11.006. Epub 2011 Nov 26. No abstract available.

PMID:
22138262
13.

Identification and validation of bioactive small molecule target through phenotypic screening.

Cho YS, Kwon HJ.

Bioorg Med Chem. 2012 Mar 15;20(6):1922-8. doi: 10.1016/j.bmc.2011.11.021. Epub 2011 Nov 20.

PMID:
22153994
14.

Current trends in epigenetic drug discovery.

Stolfa DA, Einsle O, Sippl W, Jung M.

Future Med Chem. 2012 Oct;4(16):2029-37. doi: 10.4155/fmc.12.144.

PMID:
23157236
15.

Nitric oxide and cyclic GMP signaling pathway as a focus for drug development.

Kots AY, Bian K, Murad F.

Curr Med Chem. 2011;18(22):3299-305. Review.

PMID:
21728973
16.

Troubleshooting and deconvoluting label-free cell phenotypic assays in drug discovery.

Fang Y.

J Pharmacol Toxicol Methods. 2013 Mar-Apr;67(2):69-81. doi: 10.1016/j.vascn.2013.01.004. Epub 2013 Jan 20.

PMID:
23340025
17.

Systems-based discovery advances drug development.

Waldman SA, Terzic A.

Clin Pharmacol Ther. 2013 Apr;93(4):285-7. doi: 10.1038/clpt.2013.21.

PMID:
23511779
18.

Alpine drug discovery summit: 10th Swiss Course on Medicinal Chemistry.

Müller G, Ernst B.

ChemMedChem. 2012 Dec;7(12):2237-40. doi: 10.1002/cmdc.201200501. Epub 2012 Nov 23.

PMID:
23180615
19.

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.

Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA.

Mol Psychiatry. 2012 Dec;17(12):1206-27. doi: 10.1038/mp.2012.47. Epub 2012 May 15. Review.

PMID:
22584864
20.

Toward molecular imaging-driven drug development in oncology.

de Vries EG, Oude Munnink TH, van Vugt MA, Nagengast WB.

Cancer Discov. 2011 Jun;1(1):25-8. doi: 10.1158/2159-8274.CD-11-0051. Epub 2011 Jun 1.

Supplemental Content

Support Center